Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma

Recruiting now · Early Phase 1

Conditions studied: Medulloblastoma, Childhood

In brief

Medulloblastoma (MB), a rare yet critical pediatric brain tumor, is divided into 4 molecular subgroups (WNT, SHH, Group 3, Group 4), each with distinct genetic profiles. Despite diagnostic and therapeutic advances, neurotoxicity from standard treatments (resection, radiotherapy, chemotherapy) and the need for long-term care remain challenges. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), approved for breast cancer, show potential in other tumors, but their efficacy in MB is unclear. Treatment resistance is a concern. This project aims to identify genetic markers of sensitivity to CDK4/6 inhibitors in MB, to improve therapies and overcome resistance.

Key facts

Study ID

NCT06959979

Run by

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

People needed

60

Starts

2024-11-25

Expected to finish

2026-08-31

Last updated by the study team

2025-05-07

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients affected by Medulloblastoma operated on at the Pediatric Neurosurgery Unit during their pediatric age will be elected to take part to the study

Where it is running

• Fondazione Policlinico Gemelli Irccs — Roma, ROMA, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.